Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

Paz-Ares, L.; Siena, Salvatore; Ahn, Myung‐Ju; Drilon, Alexander; Conley, Anthony P.; Rolfo, Christian; Wolf, Juergen; Seto, Takashi; Kapre, Audrey; Chen, D.; McCallum, Stewart W.; Osborne, Stuart; Demetri, George D.

doi:10.1016/j.esmoop.2021.100113

Cited by 23 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42 In terms of patient-reported QOL, global health status remained stable in patients with TRK fusion cancer who were treated with entrectinib during the phase 2 basket trial STARTRK-2. 43 Trends toward clinical improvement were were intolerant to at least 1 prior TRK inhibitor, selitrectinib treatment resulted in a 34% ORR. 44 The ORR was greater (45%) among patients with confirmed TRK kinase domain mutations.…”

Section: Overview Of Entrectinibmentioning

confidence: 99%

Diagnosis and management of TRK fusion cancer

2022

Am J Manag Care

View full text Add to dashboard Cite

Section: Overview Of Entrectinibmentioning

confidence: 99%

Diagnosis and management of TRK fusion cancer

2022

Am J Manag Care

View full text Add to dashboard Cite

“…For the 24 patients with measurable brain metastases at diagnosis, centralized assessment of the brain outcomes found ORR = 79.2% [95% CI 57.9–92.9], with median PFS at 12 months. The reported outcomes of 145 patients indicated non-clinically significant improvement of physical-function scores and quality of life (QOL; Health-Related Quality of Life scale) [ 90 ].…”

Section: Treatment Of Ros-1-positive Nsclcsmentioning

confidence: 99%

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date

et al. 2022

View full text Add to dashboard Cite

The ROS-1 gene plays a major role in the oncogenesis of numerous tumors. ROS-1 rearrangement is found in 0.9–2.6% of non-small-cell lung cancers (NSCLCs), mostly lung adenocarcinomas, with a significantly higher rate of women, non-smokers, and a tendency to a younger age. It has been demonstrated that ROS-1 is a true oncogenic driver, and tyrosine kinase inhibitors (TKIs) targeting ROS-1 can block tumor growth and provide clinical benefit for the patient. Since 2016, crizotinib has been the first-line reference therapy, with two-thirds of the patients’ tumors responding and progression-free survival lasting ~20 months. More recently developed are ROS-1-targeting TKIs that are active against resistance mechanisms appearing under crizotinib and have better brain penetration. This review summarizes current knowledge on ROS-1 rearrangement in NSCLCs, including the mechanisms responsible for ROS-1 oncogenicity, epidemiology of ROS-1-positive tumors, methods for detecting rearrangement, phenotypic, histological, and molecular characteristics, and their therapeutic management. Much of this work is devoted to resistance mechanisms and the development of promising new molecules.

show abstract

“…The European Medicines Agency also approved Entrectinib in 2020. In 2021 the patient reported outcomes findings from STARTRK-2 suggest a favorable safety profile of entrectinib with minimal treatment burden [ 26 ].…”

Section: Ntrk Inhibitormentioning

confidence: 99%

The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer

Qin

Patel

2022

IJMS

View full text Add to dashboard Cite

With the development of targeted therapy, non-small cell lung cancer (NSCLC) patients could have more treatment choices if target mutation presents. The neurotrophic tropomyosin receptor kinase (NTRK) has a low prevalence in NSCLC, roughly around 0.5%. FDA had approved two first generation NTRK inhibitors, larotrectinib and entrectinib. Both medications have excellent CNS penetration. This manuscript will review available data on targeting NTRK fusions in NSCLC and mechanisms of drug resistance.

show abstract

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

Cited by 23 publications

References 17 publications

Diagnosis and management of TRK fusion cancer

Diagnosis and management of TRK fusion cancer

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date

The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About